Rheumatology
From the Journals
Rituximab does not improve fatigue symptoms of ME/CFS
Results from the phase 3 RituxME trial found no difference in fatigue score symptoms after 24 months.
Conference Coverage
New postmenopausal osteoporosis guidelines emphasize patient priorities
NEW ORLEANS –
From the Journals
Herpes zoster risk increased with some psoriasis, psoriatic arthritis treatments
Patients with psoriasis and psoriatic arthritis may be at an increased risk of herpes zoster, particularly those treated with tofacitinib or...
From the Journals
Disease burden in OA worse than RA 6 months post presentation
RAPID3 scores improved after 6 months for both RA and OA patients, but RA patients saw greater reductions.
Conference Coverage
Concomitant methotrexate boosts pegloticase efficacy in gout patients
MAUI, HAWAII – “This really did change my practice,” said Alvin F. Wells, MD.
From the Journals
Resistant hypertension hits SLE patients hard
Higher risk for resistant hypertension goes hand in hand with higher mortality.
Conference Coverage
Recent trials advance axial spondyloarthritis therapy
MAUI, HAWAII –
From the Journals
Possible mortality risk seen with tramadol in osteoarthritis
Older patients taking tramadol for osteoarthritis had significantly higher mortality risk than did patients taking NSAIDs.
Applied Evidence
Juvenile idiopathic arthritis: Old disease, new tactics
Beyond NSAIDs and disease-modifying antirheumatic drugs are now biologic agents and anti-interleukin drugs that can augment therapy.
Clinical Inquiries
Is intra-articular platelet-rich plasma injection an effective treatment for knee OA?
EVIDENCE-BASED ANSWER: Probably not, based on the balance of evidence. While low-quality evidence may suggest potential benefit,...
News from the FDA/CDC
FDA approves liquid colchicine for gout
Physicians can easily make dose adjustments with new form of colchicine, says Romeg Therapeutics.